
Metformin (1000mg) + Linagliptin (2.5mg)
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Linagliptin inhibits the enzyme DPP-4, leading to increased levels of incretin hormones, which promote insulin secretion and inhibit glucagon release, thereby lowering blood glucose levels.
Medical applications
Justlina-M Forte Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Justlina-M Forte is prescribed as an adjunct to diet and exercise to improve glycemic parameters such as fasting blood glucose and HbA1c levels. It is particularly beneficial for patients inadequately controlled on metformin monotherapy or those requiring combination therapy to minimize the risk of hypoglycemia and weight gain. Dosage adjustments may be necessary in patients with renal or hepatic impairment. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Justlina-M Forte Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Justlina-M Forte Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
There is limited information available on the use of Justlina-M Forte Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Justlina-M Forte Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Justlina-M Forte Tablet

Metformin (1000mg) + Linagliptin (2.5mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Linagliptin inhibits the enzyme DPP-4, leading to increased levels of incretin hormones, which promote insulin secretion and inhibit glucagon release, thereby lowering blood glucose levels.
Medical applications
Justlina-M Forte Tablet is a combination oral antidiabetic medication containing Metformin 1000 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases incretin hormone levels, which in turn stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Justlina-M Forte is prescribed as an adjunct to diet and exercise to improve glycemic parameters such as fasting blood glucose and HbA1c levels. It is particularly beneficial for patients inadequately controlled on metformin monotherapy or those requiring combination therapy to minimize the risk of hypoglycemia and weight gain. Dosage adjustments may be necessary in patients with renal or hepatic impairment. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Linagliptin is generally well tolerated. Regular monitoring of blood glucose and renal function is recommended during therapy to ensure safety and efficacy.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Justlina-M Forte Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Justlina-M Forte Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Medical Advice
There is limited information available on the use of Justlina-M Forte Tablet in patients with kidney disease. Please consult your doctor.
Exercise Caution
Your ability to drive may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Consult Doctor
There is limited information available on the use of Justlina-M Forte Tablet in patients with liver disease. Please consult your doctor.
Regular Checkup
0 reviews for Justlina-M Forte Tablet













